RENATA PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 759.9 BDT | -3.00% |
|
-5.06% | -37.61% |
| Feb. 13 | Renata Limited will Change its Name to Renata PLC | CI |
| Jan. 27 | Renata Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
| Sales 2024 * | 36.96B 336M | Sales 2025 * | 42.31B 385M | Capitalization | 87.16B 793M |
|---|---|---|---|---|---|
| Net income 2024 * | 4.07B 37.02M | Net income 2025 * | 5.25B 47.79M | EV / Sales 2024 * | 2.36 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
16.6
x | Employees | 7,119 |
| Yield 2024 * |
0.7% | Yield 2025 * |
0.91% | Free-Float | 15.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.00% | ||
| 1 week | -5.06% | ||
| Current month | -2.07% | ||
| 1 month | -6.98% | ||
| 3 months | -37.61% | ||
| 6 months | -37.61% | ||
| Current year | -37.61% |
1 week
759.90
800.40
1 month
730.00817.00
Current year
730.001 217.90
1 year
730.001 217.90
3 years
730.001 289.72
5 years
730.001 289.72
10 years
312.791 289.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01-12-31 | |
| Director of Finance/CFO | - | - | |
| Chief Tech/Sci/R&D Officer | - | 10-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01-12-31 | |
Sarwar Ali
CHM | Chairman | 82 | 93-12-31 |
| Director/Board Member | - | 13-08-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 759.9 | -3.00% | 16,127 |
| 24-04-24 | 783.4 | -0.44% | 3,235 |
| 24-04-23 | 786.9 | +0.49% | 6,379 |
| 24-04-22 | 783.1 | +0.09% | 4,707 |
| 24-04-21 | 782.4 | -2.25% | 4,985 |
End-of-day quote Dhaka S.E., April 24, 2024
More quotes
Renata PLC, formerly Renata Limited, is a Bangladesh-based pharmaceutical and animal health company. The Company is engaged in manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products, and consumer products. The Company also engages in the business as traders, importers, exporters, commission agents of all kinds of goods and services, including pharmaceutical drugs and medicines. Its offerings include Algin Injection, Algin Syrup, Alphapress Tablet, Androcap Capsule, Becosules Capsule, Bredicon Tablet, Cabolin Tablet, Anorexon Tablet, Aquastar Growout Powder, Avinex Powder, Catophos Injection, Eggshell Tmo Powder, Ectorid Injection, Doxivet Powder, Fevenil Injection, Fluximine Injection, Cardipin Tablet, Cartilage Plus Tablet, and Diadin Injection, among others.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
759.9
BDT
Average target price
1,109
BDT
Spread / Average Target
+45.94%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.61% | 819M | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- RENATA Stock
